Fig. 2From: Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibodyBiodistribution of 89Zr-labelled-RG7356. a As function of time: maximum intensity projections at 1, 24 and 96 h p.i. for patient 12 (675 mg dose cohort). b As function of total administered antibody dose: maximum intensity projections at 96 h p.i. for various dose cohorts (1, 100, 200, 450 and 675 mg)Back to article page